# Special Drug Use Investigation of EYLEA for Diabetic Macular Edema

> **NCT02425501** · — · COMPLETED · sponsor: **Bayer** · enrollment: 646 (actual)

## Conditions studied

- Macular Edema

## Interventions

- **DRUG:** Aflibercept (Eylea, BAY86-5321)

## Key facts

- **NCT ID:** NCT02425501
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-20
- **Primary completion:** 2019-04-26
- **Final completion:** 2019-08-13
- **Target enrollment:** 646 (ACTUAL)
- **Last updated:** 2023-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02425501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02425501, "Special Drug Use Investigation of EYLEA for Diabetic Macular Edema". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02425501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*